|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-8.96/-7.95
|
企业价值
87.07M
|
资产负债 |
每股账面净值
3.34
|
现金流量 |
现金流量率
--
|
损益表 |
收益
10.02M
|
每股收益
1.73
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/04/29 06:51 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advancedsolid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. |